Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Atadja

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Blood|June 21, 2003
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaLaurence Catley, Ellen Weisberg, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Elife|August 3, 2017
FXR1 regulates transcription and is required for growth of human cancer cells with <i>TP53/FXR2</i> homozygous deletionYichao Fan, Jiao Yue, Mengtao Xiao, et al.
Cancer Research|January 28, 2004
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824Peter Atadja, Lin Gao, Paul Kwon, et al.
Cancer Research|August 4, 2006
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomographyJulius Leyton, John P Alao, Marco Da Costa, et al.
Blood|January 14, 2014
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsMichael Bots, Inge Verbrugge, Benjamin P Martin, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|November 19, 2022
Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targetsLulu Liu, Xin Guo, Yao Wang, et al.
Haematologica|December 3, 2009
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEnrique M Ocio, David Vilanova, Peter Atadja, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Blood|June 21, 2003
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaLaurence Catley, Ellen Weisberg, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Elife|August 3, 2017
FXR1 regulates transcription and is required for growth of human cancer cells with <i>TP53/FXR2</i> homozygous deletionYichao Fan, Jiao Yue, Mengtao Xiao, et al.
Cancer Research|January 28, 2004
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824Peter Atadja, Lin Gao, Paul Kwon, et al.
Cancer Research|August 4, 2006
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomographyJulius Leyton, John P Alao, Marco Da Costa, et al.
Blood|January 14, 2014
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsMichael Bots, Inge Verbrugge, Benjamin P Martin, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|November 19, 2022
Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targetsLulu Liu, Xin Guo, Yao Wang, et al.
Haematologica|December 3, 2009
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEnrique M Ocio, David Vilanova, Peter Atadja, et al.
Pageof 11